Standard and Interpretation
Recommendations for the diagnosis and treatment of gout in China
Xu Dong, Zhu Xiaoxia, Zou Hejian, Lin He, Zhao Yan, on behalf of Chinese Rheumatology Association
Published 2023-09-01
Cite as Chin J Intern Med, 2023, 62(9): 1068-1076. DOI: 10.3760/cma.j.cn112138-20221027-00796
Abstract
Gout is a metabolic disease resulting from the accumulation of monosodium urate (MSU) in joints, leading to crystal-induced arthritis. In China, gout is common, but there is insufficient knowledge regarding standardized criteria for the diagnosis and treatment of this condition. Based on evidence and guidelines from China and other countries, the Chinese Rheumatology Association developed standardized criteria for the diagnosis and treatment of gout in China. The purpose was to standardize gout diagnosis methods as well as treatment opportunities and strategies in order to reduce misdiagnosis, missed diagnosis, and irreversible damage.
Key words:
Gout; Hyperuricemia; Diagnosis; Treatment; Prognosis
Contributor Information
Xu Dong
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science &
Technology,State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education,Beijing 100730, China
Zhu Xiaoxia
Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai 200040, China
Zou Hejian
Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai 200040, China
Lin He
Department of Rheumatology,Fujian Provincial Hospital, Fuzhou 350013, China
Zhao Yan
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science &
Technology,State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education,Beijing 100730, China
on behalf of Chinese Rheumatology Association
